The Scottish Medicines Consortium (SMC) does not recommend rosuvastatin (Crestor®) for use in NHS Scotland for the prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event as an adjunct to correction of other risk factors. The SMC notes that in a randomised, placebo-controlled, double-blind, multi-centre study, treatment with rosuvastatin was associated with a significantly reduced risk of first cardiovascular event versus placebo in patient sub-groups deemed to be high-risk when assessed using the Framingham equation and the SCORE algorithm. However, the submitting company did not present sufficiently robust economic analysis to gain acceptance by SMC.